|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC14 |
Gene summary for CCDC14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC14 | Gene ID | 64770 |
| Gene name | coiled-coil domain containing 14 | |
| Gene Alias | CCDC14 | |
| Cytomap | 3q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | Q49A88 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64770 | CCDC14 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.52e-10 | -9.97e-01 | -0.2061 |
| 64770 | CCDC14 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.26e-07 | -9.38e-01 | -0.1462 |
| 64770 | CCDC14 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.50e-09 | -8.15e-01 | -0.0842 |
| 64770 | CCDC14 | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.93e-05 | -1.06e+00 | -0.00410000000000005 |
| 64770 | CCDC14 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.24e-14 | -1.03e+00 | -0.0179 |
| 64770 | CCDC14 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.21e-35 | -9.84e-01 | 0.096 |
| 64770 | CCDC14 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.52e-08 | -1.03e+00 | 0.0446 |
| 64770 | CCDC14 | HTA11_9408_2000001011 | Human | Colorectum | AD | 6.01e-07 | -1.11e+00 | 0.0451 |
| 64770 | CCDC14 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.25e-13 | -1.10e+00 | 0.0528 |
| 64770 | CCDC14 | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.19e-06 | -8.55e-01 | 0.0131 |
| 64770 | CCDC14 | HTA11_10623_2000001011 | Human | Colorectum | AD | 7.01e-06 | -7.36e-01 | -0.0177 |
| 64770 | CCDC14 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.05e-21 | -9.32e-01 | 0.0338 |
| 64770 | CCDC14 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.52e-48 | -9.49e-01 | 0.0674 |
| 64770 | CCDC14 | HTA11_6818_2000001011 | Human | Colorectum | AD | 6.54e-11 | -9.52e-01 | 0.0112 |
| 64770 | CCDC14 | HTA11_11156_2000001011 | Human | Colorectum | AD | 6.22e-06 | -1.14e+00 | 0.0397 |
| 64770 | CCDC14 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.85e-20 | -1.03e+00 | 0.0588 |
| 64770 | CCDC14 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.18e-11 | -5.17e-01 | 0.294 |
| 64770 | CCDC14 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.61e-11 | -6.61e-01 | 0.281 |
| 64770 | CCDC14 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.04e-41 | -9.03e-01 | 0.3859 |
| 64770 | CCDC14 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.70e-22 | -1.14e+00 | 0.2585 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00309019 | Cervix | CC | midbrain development | 26/2311 | 90/18723 | 2.12e-05 | 3.82e-04 | 26 |
| GO:002176210 | Cervix | CC | substantia nigra development | 16/2311 | 44/18723 | 3.81e-05 | 5.99e-04 | 16 |
| GO:00488579 | Cervix | CC | neural nucleus development | 18/2311 | 64/18723 | 5.42e-04 | 5.23e-03 | 18 |
| GO:0021762 | Colorectum | AD | substantia nigra development | 21/3918 | 44/18723 | 6.60e-05 | 1.07e-03 | 21 |
| GO:0048857 | Colorectum | AD | neural nucleus development | 27/3918 | 64/18723 | 9.57e-05 | 1.45e-03 | 27 |
| GO:0071539 | Colorectum | AD | protein localization to centrosome | 16/3918 | 33/18723 | 3.86e-04 | 4.41e-03 | 16 |
| GO:1905508 | Colorectum | AD | protein localization to microtubule organizing center | 16/3918 | 35/18723 | 8.76e-04 | 8.51e-03 | 16 |
| GO:0030901 | Colorectum | AD | midbrain development | 32/3918 | 90/18723 | 9.45e-04 | 8.95e-03 | 32 |
| GO:00217621 | Colorectum | SER | substantia nigra development | 21/2897 | 44/18723 | 4.77e-07 | 2.40e-05 | 21 |
| GO:00488571 | Colorectum | SER | neural nucleus development | 26/2897 | 64/18723 | 1.09e-06 | 5.11e-05 | 26 |
| GO:00309011 | Colorectum | SER | midbrain development | 29/2897 | 90/18723 | 5.50e-05 | 1.30e-03 | 29 |
| GO:00217622 | Colorectum | MSS | substantia nigra development | 21/3467 | 44/18723 | 9.54e-06 | 2.33e-04 | 21 |
| GO:00488572 | Colorectum | MSS | neural nucleus development | 26/3467 | 64/18723 | 3.19e-05 | 6.30e-04 | 26 |
| GO:00715391 | Colorectum | MSS | protein localization to centrosome | 16/3467 | 33/18723 | 8.66e-05 | 1.40e-03 | 16 |
| GO:19055081 | Colorectum | MSS | protein localization to microtubule organizing center | 16/3467 | 35/18723 | 2.07e-04 | 2.89e-03 | 16 |
| GO:00309012 | Colorectum | MSS | midbrain development | 31/3467 | 90/18723 | 2.36e-04 | 3.24e-03 | 31 |
| GO:0044380 | Colorectum | MSS | protein localization to cytoskeleton | 19/3467 | 58/18723 | 6.69e-03 | 4.38e-02 | 19 |
| GO:0072698 | Colorectum | MSS | protein localization to microtubule cytoskeleton | 18/3467 | 54/18723 | 6.70e-03 | 4.38e-02 | 18 |
| GO:00715392 | Colorectum | FAP | protein localization to centrosome | 14/2622 | 33/18723 | 6.39e-05 | 1.23e-03 | 14 |
| GO:19055082 | Colorectum | FAP | protein localization to microtubule organizing center | 14/2622 | 35/18723 | 1.38e-04 | 2.18e-03 | 14 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC14 | SNV | Missense_Mutation | c.1394G>C | p.Arg465Thr | p.R465T | Q49A88 | protein_coding | deleterious(0.01) | benign(0.096) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| CCDC14 | SNV | Missense_Mutation | rs372947520 | c.2045N>G | p.Thr682Ser | p.T682S | Q49A88 | protein_coding | tolerated(0.53) | benign(0) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCDC14 | SNV | Missense_Mutation | c.116N>G | p.Ser39Trp | p.S39W | Q49A88 | protein_coding | tolerated_low_confidence(0.2) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CCDC14 | SNV | Missense_Mutation | novel | c.806N>C | p.Gly269Ala | p.G269A | Q49A88 | protein_coding | tolerated(0.24) | benign(0.027) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| CCDC14 | SNV | Missense_Mutation | c.679N>T | p.Pro227Ser | p.P227S | Q49A88 | protein_coding | tolerated(0.81) | benign(0.046) | TCGA-B6-A0WV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC14 | SNV | Missense_Mutation | c.1682N>C | p.Leu561Pro | p.L561P | Q49A88 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC14 | SNV | Missense_Mutation | c.2129N>T | p.Ser710Phe | p.S710F | Q49A88 | protein_coding | tolerated(0.62) | benign(0.146) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| CCDC14 | SNV | Missense_Mutation | c.1269N>G | p.Ile423Met | p.I423M | Q49A88 | protein_coding | deleterious(0.02) | possibly_damaging(0.882) | TCGA-E9-A1RA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CCDC14 | deletion | Frame_Shift_Del | c.228delA | p.Ala77ArgfsTer4 | p.A77Rfs*4 | Q49A88 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |||
| CCDC14 | insertion | Frame_Shift_Ins | novel | c.1883_1884insGTCTCTCCCTCCTCTAATCCTTCCTATTTACT | p.Leu631ProfsTer12 | p.L631Pfs*12 | Q49A88 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |